Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Non-Current Liabilities (2017)

Viking Therapeutics (VKTX) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $47113.0 as the latest value for Q1 2017.

  • For Q1 2017, Other Non-Current Liabilities fell 76.78% year-over-year to $47113.0; the TTM value through Mar 2017 reached $47113.0, down 76.78%, while the annual FY2015 figure was $183611.0, N/A changed from the prior year.
  • Other Non-Current Liabilities hit $47113.0 in Q1 2017 for Viking Therapeutics, down from $202882.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $202882.0 in Q1 2016 and bottomed at $47113.0 in Q1 2017.
  • Average Other Non-Current Liabilities over 3 years is $144535.3, with a median of $183611.0 recorded in 2015.
  • On a YoY basis, Other Non-Current Liabilities climbed as much as 76.78% in 2017 and fell as far as 76.78% in 2017.
  • Viking Therapeutics' Other Non-Current Liabilities stood at $183611.0 in 2015, then increased by 10.5% to $202882.0 in 2016, then plummeted by 76.78% to $47113.0 in 2017.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $47113.0, $202882.0, and $183611.0 for Q1 2017, Q1 2016, and Q4 2015 respectively.